Buchumschlag

Neoadjuvant and adjuvant chemotherapy in pancreatic cancer

Only 15-20% of patients with pancreatic ductal adenocarcinoma (PDAC) have a resectable tumor at the time of diagnosis. Effective multimodal treatment concepts including neoadjuvant chemotherapy are therefore needed. Following upfront resection, adjuvant chemotherapy has become mandatory to prevent e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Klaiber, Ulla (VerfasserIn) , Leonhardt, Carl-Stephan (VerfasserIn) , Strobel, Oliver (VerfasserIn) , Tjaden, Christin (VerfasserIn) , Hackert, Thilo (VerfasserIn) , Neoptolemos, John P. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 5 November 2018
In: Langenbeck's archives of surgery
Year: 2018, Jahrgang: 403, Heft: 8, Pages: 917-932
ISSN:1435-2451
DOI:10.1007/s00423-018-1724-8
Online-Zugang:Resolving-System, Volltext: https://doi.org/10.1007/s00423-018-1724-8
Verlag: https://link.springer.com/article/10.1007%2Fs00423-018-1724-8
Volltext
Verfasserangaben:Ulla Klaiber, Carl-Stephan Leonhardt, Oliver Strobel, Christine Tjaden, Thilo Hackert, John P. Neoptolemos
Beschreibung
Zusammenfassung:Only 15-20% of patients with pancreatic ductal adenocarcinoma (PDAC) have a resectable tumor at the time of diagnosis. Effective multimodal treatment concepts including neoadjuvant chemotherapy are therefore needed. Following upfront resection, adjuvant chemotherapy has become mandatory to prevent early tumor recurrence. The aim of this article was to summarize existing evidence on neoadjuvant and adjuvant chemotherapy in PDAC with a focus on high-level evidence based on randomized controlled phase III clinical trials.
Beschreibung:Gesehen am 25.10.2019
Beschreibung:Online Resource
ISSN:1435-2451
DOI:10.1007/s00423-018-1724-8

Ähnliche Einträge